文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

锝-99m骨闪烁显像在疑似心脏淀粉样变中的应用

Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis.
PubMed 文献 · Eur Heart J · 2023-01-01

多国回顾性研究纳入3354例疑似或组织学证实的心脏淀粉样变患者,评估基于骨闪烁显像的非活检诊断标准(NBDC)对ATTR-CM的特异性为97%(95%CI 0.91-0.99),并利用纳入eGFR的修订sFLC比值切点优化单克隆丙种球蛋白病排除。

要点

  • 骨闪烁显像2或3级且免疫固定电泳阴性、sFLC比值在修订切点内,可无活检诊断ATTR-CM。
  • 0级扫描几乎排除ATTR-CM,但多数AL-CA患者呈0级。
  • 1级扫描无单克隆丙种球蛋白病者强烈提示早期ATTR型,需紧急组织学证实。

核心结论

  • ATTR-CM的非活检诊断标准在临床环境中特异性达97%(95%CI 0.91-0.99)。
  • 纳入eGFR的修订sFLC比值切点可进一步优化慢性肾脏病患者中单克隆丙种球蛋白病的排除。

研究设计与样本

  • 多国回顾性研究,纳入2015至2021年转诊至专科中心的3354例疑似或组织学证实的心脏淀粉样变患者。
  • 评估包括放射性核素骨闪烁显像、血清和尿液免疫固定电泳、sFLC检测、eGFR测量和超声心动图。

主要发现

  • 上述患者中403例活检有淀粉样物质,均为ATTR型,其生存与未活检ATTR-CM患者相当(p = 0.10)。
  • 1091例0级扫描患者中284例(26%)有心脏淀粉样变,其中276例(97%)为AL型,仅1例为极罕见TTR变异所致ATTR-CM。
  • 183例1级扫描患者中,122例有单克隆丙种球蛋白病,其中106例(87%)为AL-CA;无单克隆丙种球蛋白病的61例中60例(98%)为ATTR-CM。

关键数值与推荐

  • ATTR-CM非活检诊断标准:骨闪烁显像Perugini 2或3级,血清和尿液免疫固定电泳无单克隆蛋白,sFLC比值在纳入eGFR的修订切点内。
  • NBDC对ATTR-CM的特异性为97%(95%CI 0.91-0.99)。

临床怎么用

  • 对疑似心脏淀粉样变患者,可依据骨闪烁显像分级结合免疫固定电泳和sFLC比值(含eGFR修订切点)无活检诊断ATTR-CM。
  • 0级扫描几乎排除ATTR-CM,但需警惕AL-CA可能。
  • 1级扫描且无单克隆丙种球蛋白病者强烈提示早期ATTR型,应紧急行组织学证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To perform evaluation of widely embraced bone scintigraphy-based non-biopsy diagnostic criteria (NBDC) for ATTR amyloid cardiomyopathy (ATTR-CM) in clinical practice, and to refine serum free light chain (sFLC) ratio cut-offs that reliably exclude monoclonal gammopathy (MG) in chronic kidney disease. METHODS AND RESULTS: A multi-national retrospective study of 3354 patients with suspected or histologically proven cardiac amyloidosis (CA) referred to specialist centres from 2015 to 2021; evaluations included radionuclide bone scintigraphy, serum and urine immunofixation, sFLC assay, eGFR measurement and echocardiography. Seventy-nine percent (1636/2080) of patients with Perugini grade 2 or 3 radionuclide scans fulfilled NBDC for ATTR-CM through absence of a serum or urine monoclonal protein on immunofixation together with a sFLC ratio falling within revised cut-offs incorporating eGFR; 403 of these patients had amyloid on biopsy, all of which were ATTR type, and their survival was comparable to non-biopsied ATTR-CM patients (p = 0.10). Grade 0 radionuclide scans were present in 1091 patients, of whom 284 (26%) had CA, confirmed as AL type (AL-CA) in 276 (97%) and as ATTR-CM in only one case with an extremely rare TTR variant. Among 183 patients with grade 1 radionuclide scans, 122 had MG of whom 106 (87%) had AL-CA; 60/61 (98%) without MG had ATTR-CM. CONCLUSION: The NBDC for ATTR-CM are highly specific [97% (95% CI 0.91-0.99)] in clinical setting, and diagnostic performance was further refined here using new cut-offs for sFLC ratio in patients with CKD. A grade 0 radionuclide scan all but excludes ATTR-CM but occurs in most patients with AL-CA. Grade 1 scans in patients with CA and no MG are strongly suggestive of early ATTR-type, but require urgent histologic corroboration.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Rauf MU, Hawkins PN, Cappelli F, et al. Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis. Eur Heart J. 2023. PMID: 36946431. doi:10.1093/eurheartj/ehad139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。